Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Clin Cancer Res. 2019 Dec 18;26(5):1094–1104. doi: 10.1158/1078-0432.CCR-19-0909

Figure 5: Comparison of somatic alterations in 24 matched patient tumors and derivative PDX.

Figure 5:

(A) Somatic mutations and CNVs involving core glioma associated genes. Matched patient (P) and derivative PDX (X) models are adjacent for each pair. The GBM195 patient-PDX pair is also shown with GBM209 (209X), a PDX line established from the patient’s subsequent tumor recurrence. (B) Representative scatterplots comparing variant allele frequency (VAF) of four patient-PDX pairs. The four selected pairs reflect the spectrum of SNV conservation across the matched patient-PDX pairs. (C) FISH of matched patient and PDX tissue showing subclonal amplifications of N-MYC (GBM110) and PDGFRA (GBM159). Two distinct PDGFRA amplified subclones could be distinguished in the patient tumor by involvement of the centromeric probe (CEP4). %Amp denotes the percentage of tumor cells with >8 copies of the target probe with range given across 3 patient tumor blocks.